RareStone announced that
RareStone and Biogen are named the winner of the Golden Snail Award 2022. Sponsored by the Chinese Organization for Rare Disorders, the prestigious Golden Snail Award is the first award in China to recognize outstanding contributors to rare diseases.
Aiming to improve the lives of patients and families impacted by rare diseases, RareStone is building a "
RareDisease 2.0 Company" focused on efficient R&D and innovative commercialization of rare disease drugs. RareStone has built a portfolio of 7 products via external collaboration and in-house development. In addition, RareStone aims to provide total solutions to rare disease patients and families beyond just drugs. Zircon Health, a subsidiary of RareStone, has leveraged digital tools, big data, and artificial intelligence technologies to help the rare disease community in China improve access to knowledge, care, payment, and non-treatment solutions. For example, the Zircon Internet Hospital for Rare Diseases and Zircon Rare Disease Wikipedia have helped thousands of patients in China since launch in 2021.
"The Golden Snail Award acknowledges RareStone's pioneering efforts to build the rare disease ecosystem in China with all partners in the industry ", said Shawn Xiang, CEO of RareStone Group. "There's still much to do, and we're committed to bringing more innovative, affordable solutions and hope to Chinese patients and families."